ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1982

Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Abstract Number: 1928

Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis
Abstract Number: 1723

RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data
Abstract Number: 1702

RA-Related Knowledge and Skills of Rheumatology Fellows Among 20 US Academic Institutions
Abstract Number: 0843

Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Abstract Number: 0844

Rab4A Regulates Glomerulonephritis and Tryptophan Metabolism in Sle1.2.3. Lupus-prone Mice via Recycling of CD98
Abstract Number: 0006

Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Abstract Number: 0042

Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity
Abstract Number: 1017

Racial and Ethnic Disparities in the Risk of Preterm Birth Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis with Varying Reference Groups
Abstract Number: 0055

Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm
Abstract Number: 0433

Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus
Abstract Number: 1644

Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
Abstract Number: 1231

Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years
Abstract Number: 1895

Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Abstract Number: 1235

Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].